Drug Trial Radar · NCT05593614
Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)
Last checked: Nov 19, 2026Latest source record: Jul 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
276
Actual
Start
Feb 28, 2023
Primary completion
Sep 2024
Study completion Sep 2024
Sponsor
- Lead sponsor
- AlgoTherapeutixIndustry
- Sponsor type
- Industry
- First posted
- Oct 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to compare the efficacy of twice daily applications of ATX01 (10% \& 15%) versus placebo during a 12-week treatment period in treating chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivor patients.
Conditions
- Chemotherapy-induced Peripheral Neuropathy
Interventions
ATX01 10%Drug
A 100 mL bottle of hydrogel formulation containing 10% amitriptyline hydrochloride w/w
ATX01 15%Drug
A 100 mL bottle of hydrogel formulation containing 15% amitriptyline hydrochloride w/w
PlaceboDrug
A 100 mL bottle of hydrogel formulation containing no active substance
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline to Week 12 in the weekly mean of the daily NPRS score assessing average pain intensity in target study extremities related to CIPN in the past 24 hours.Time frame: 12 weeks
Locations
43 sites in 7 countries. Site status is shown where the registry gives one.
South Lake Pain Institute
Clermont, Florida
MGM Medical Care Research & Rehab, LLC
Miami, Florida
Medsol Clinical Research Center, Inc
Port Charlotte, Florida
Knight Neurology - Clinical Research
Rockledge, Florida
Neuroscience Research Center, LLC.
Overland Park, Kansas
The Center for Cancer and Blood Disorders (CCBD)
Bethesda, Maryland
University of Rochester Medical Center
Rochester, New York
HD Research
Bellaire, Texas
OLV Hospital Aalst: gastro-enterologie
Aalst, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
Universitair Ziekenhuis Gent (UZ Gent)
Ghent, Belgium
UZ Leuven / Campus Pellenberg / Pain Center
Pellenberg, Belgium
CHU UCL Namur - site Godinne
Yvoir, Belgium
Clinitrial s.r.o.
Prague, Czechia
Praglandia s.r.o.
Prague, Czechia
Nemocnice Teplice
Teplice, Czechia
Centre Hospitalier de la Côte Basque
Bayonne, France
Institute Bergonie
Bordeaux, France
CHU de Montpellier, Hôpital Saint Eloi
Montpellier, France
Groupe Hospitalier Paris Saint Joseph
Paris, France
CHU POITIERS, Hépato-Gastro Entérologie
Poitiers, France
GODINOT Institute
Reims, France
Strasbourg Oncologie Liberale
Strasbourg, France
Hôpital Foch
Suresnes, France
Gemelli Molise S.p.a.
Campobasso, Italy
Istituto Scientifico Romagnolo per lo Studio e La cura dei Tumori Srl (IRST)
Meldola, Italy
Fondazione IRCCS Ca' Granda Ospedale -. Maggiore Policlinico
Milan, Italy
ASST Monza - Ospedale S. Gerardo di Monza
Monza, Italy
Fondazione IRCCS Policlinico San Matteo - Universita degli Studi di Pavia
Pavia, Italy
Azienda Ospedaliera San Camillo-Forlanini
Roma, Italy
Przychodnia Lekarska "Komed" Roman Karaszewski Oddzial Chemioterapii Jednego Dnia
Konin, Poland
Instytut "Centrum Zdrowia Matki Polki" Klinika Onkologii
Lodz, Poland
Niepubliczny Zaklad Opieki Zdrowotnej Poradnia Leczenia Bolu Przewleklego
Tychy, Poland
ClinHouse sp z o.o. - ClinHouse Centrum Medyczne
Zabrze, Poland
Hospital de la Santa Creu I de Sant Pau
Barcelona, Spain
Hospital Universitari de Bellvitge
Barcelona, Spain
Hospital Universitario Reina Sofia
Córdoba, Spain
Complejo Hospitalarion de Jaen
Jaén, Spain
Hospital General Universitario Gregorio Maranon
Madrid, Spain
Hospital Ruber Internacional
Madrid, Spain
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.